skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Special Considerations Regarding the Use of Antiretroviral Drugs by HIV-Infected Pregnant Women and Their Infants

Protease Inhibitor Therapy and Hyperglycemia

(Last updated: July 31, 2012; last reviewed: July 31, 2012)

Panel's Recommendations

Panel's Recommendation

  • HIV-infected women taking antiretroviral drug regimens during pregnancy should undergo standard glucose screening at 24 to 28 weeks’ gestation (AIII). Some experts would perform earlier glucose screening in women receiving ongoing protease inhibitor-based regimens initiated before pregnancy, similar to recommendations for women with high risk factors for glucose intolerance (BIII).
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Hyperglycemia, new-onset diabetes mellitus, exacerbation of existing diabetes mellitus, and diabetic ketoacidosis have been reported in HIV-infected patients taking protease inhibitors (PIs).1-4 In addition, pregnancy is itself a risk factor for hyperglycemia. To date, however, the majority of studies have not shown an increased risk of glucose intolerance with PI-based regimens during pregnancy. One small retrospective study that included 41 women receiving PI-based combination antiretroviral (ARV) regimens found an increased risk of glucose intolerance, but not gestational diabetes, among women on combination ARV regimens compared with zidovudine alone,5 although 2 other retrospective studies did not find an increased risk of glucose intolerance with PIs.6,7 Secondary analyses of 2 large cohorts did not find an association between the type of ARV regimen and gestational diabetes, except for an association between initiation of PIs before pregnancy or during the first trimester and gestational diabetes in the PACTG 316 cohort.8,9 Finally, a prospective study including detailed evaluations for glucose intolerance and insulin resistance among HIV-infected pregnant women did not find differences between women on PI-containing and non-PI-containing regimens.10 In both groups, however, the rate of impaired glucose tolerance was high (38%), likely related to high body mass index and race/ethnicity among trial subjects.

HIV-infected women receiving ARV regimens during pregnancy should receive standard glucose screening at 24 to 28 weeks’ gestation. Some experts would perform earlier glucose screening in women with ongoing PI-based ARV regimens initiated before pregnancy (particularly those of minority race/ethnicity), similar to recommendations for women with high risk factors for glucose intolerance, such as maternal obesity, advanced maternal age, and family history of type II diabetes mellitus.

References

  1. Food and Drug Administration. FDA Public Health Advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for treatment of human immunodeficiency virus (HIV). Food and Drug Administration, Public Health Service, Department of Health and Human Services. Rockville, MD: June 11, 1997. Available at http://www.fda.gov/cder/news/proteaseletter.htm.
  2. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. Nov 15 1997;127(10):947. Available at http://www.ncbi.nlm.nih.gov/pubmed/9382374.
  3. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med. Nov 15 1997;127(10):948. Available at http://www.ncbi.nlm.nih.gov/pubmed/9382376.
  4. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies. AIDS Clin Care. Jun 1998;10(6):41-44. Available at http://www.ncbi.nlm.nih.gov/pubmed/11365497.
  5. Chmait R, Franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol. Jul-Aug 2002;22(5):370-373. Available at http://www.ncbi.nlm.nih.gov/pubmed/12082471.
  6. Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol. 2002;10(4):187-191. Available at http://www.ncbi.nlm.nih.gov/pubmed/12648312.
  7. Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol. May 2006;107(5):1115-1119. Available at http://www.ncbi.nlm.nih.gov/pubmed/16648418.
  8. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. Apr 1 2005;38(4):449-473. Available at http://www.ncbi.nlm.nih.gov/pubmed/15764963.
  9. Watts DH, Balasubramanian R, Maupin RT, Jr., et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. Feb 2004;190(2):506-516. Available at http://www.ncbi.nlm.nih.gov/pubmed/14981398.
  10. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. Apr 2007;196(4):331 e331-337. Available at http://www.ncbi.nlm.nih.gov/pubmed/17403409

Back to Top